Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1

• US 20130066058A1
• Filed: 08/10/2012
• Published: 03/14/2013
• Est. Priority Date: 07/23/2001
• Status: Abandoned Application

• Current Assignee: Adrienne Boone, Bruce C. Galton, Catherine Taylor, Dominic Cliche, Elizabeth Margaret Heikkila, John E Thompson, John Gerard Flannagan, Michelle Senchyna, Shelley Culp-Stewart
• Original Assignee: Adrienne Boone, Bruce C. Galton, Catherine Taylor, Dominic Cliche, Elizabeth Margaret Heikkila, John E Thompson, John Gerard Flannagan, Michelle Senchyna, Shelley Culp-Stewart
• Inventors: Thompson, John E., Galton, Bruce C., Taylor, Catherine, Boone, Adrienne, Heikkila, Elizabeth Margaret, Cliche, Dominic, Culp-Stewart, Shelley, Senchyna, Michelle, Flannagan, John Gerard
• Application Number:
  US13/572,123
• Publication Number:
  US 20130066058A1
• Time in Patent Office: Days
• US Class Current: 536/24.5
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 15/113 : Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/11 : Antisense
• CPC Class Codes: C12N 2310/14 : interfering N.A.
• CPC Class Codes: C12N 2310/53 : partially self-complementary or closed

Abstract

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.

Claims

1-36. -36. (canceled)

37. An siRNA for suppressing expression of apoptosis-specific eIF-5A1 wherein the siRNA is double-stranded for 19-25 nucleotides in length.

38. The siRNA of claim 37, wherein the siRNA has at least one single-stranded overhang region, with each single-stranded region comprising six or fewer nucleotides.

39. The siRNA of claim 38, wherein the siRNA has two single-stranded overhang regions.

40. The siRNA of claim 39, wherein each of the two single-stranded overhang regions comprise two nucleotides or less.

41. The siRNA of claim 40, wherein the double-stranded region on the siRNA is 19-21 nucleotides in length.

42. The siRNA of claim 41, wherein the double-stranded region on the siRNA is 21 nucleotides in length.

43. The siRNA of claim 41, wherein the double-stranded region on the siRNA is 19 nucleotides in length.